Nuformix PLC (GB00BYW79Y38)

Overview

Nuformix plc is a pharmaceutical development company based in London, United Kingdom, focusing on the repurposing of drugs for new therapeutic fields, specifically in treating fibrosis and oncology. Founded in 2008, Nuformix plc employs a strategy of drug repurposing, which involves finding new uses for existing drugs, thus potentially bringing therapies to market more quickly and at a lower cost than developing new drugs from scratch. The company's work in drug repurposing aims to address unmet medical needs in oncology supportive care and the treatment of idiopathic pulmonary fibrosis, among other conditions.

Products and Services

NXP001: Completed Phase 1 clinical trial for use in oncology supportive care. This product is a repurposed drug, though the specific original drug and the new indication it is being repurposed for within oncology supportive care is not detailed, the completion of Phase 1 implies safety in humans has been assessed for the new use.

NXP004: A novel form of Olaparib that is currently in the Intellectual Property (IP) generation phase for treating oncology. Olaparib is a PARP inhibitor, commonly used in the treatment of cancer by blocking DNA repair and promoting cancer cell death. Nuformix’s development of NXP004 indicates a new formulation or application of Olaparib, aiming to provide benefits over existing versions of the drug.

NXP002: In the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis, an area with significant unmet medical need. NXP002 represents Nuformix’s efforts to find new treatments for this chronic and ultimately fatal disease by repurposing an existing drug, although the original drug is not specified.

Oxilio Ltd. Option Agreement for NXP001: Nuformix has entered into an option agreement with Oxilio Ltd. for the oncology indications of NXP001. This partnership indicates recognition of NXP001's potential in oncology applications and provides a pathway towards further development and commercialization.